Sep 8, 2021

Featuring perspectives from Drs Mark Awad, David R Spigel and Heather Wakelee, including the following topis:

• Immunotherapy in the (Neo)Adjuvant Setting
  • Introduction (0:00)
  • Case: A woman in her mid-60s with adenocarcinoma of the lung — PD-L1 of 0 — Sulfi Ibrahim, MD (1:39)
  • Key relevant data sets (11:36)
• First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation
  • Case: A woman in her mid-60s with adenocarcinoma of the lung — PD-L1 of 0 (continued) — Dr Ibrahim (16:34)
  • Case: A woman in her mid-60s with metastatic squamous cell carcinoma of the lung — PD-L1 75% — Margaret Deutsch, MD (22:42)
  • Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung and brain metastases — PD-L1 90% — Joseph Martins, MD (25:44)
  • Case: A man in his early 70s with recurrent metastatic adenocarcinoma of the lung — TP53 and KRAS G12A mutations — Raymond Lobins, DO (30:05)
  • Case: A man in his mid-60s with metastatic adenocarcinoma of the lung and active hepatitis C — Maria Regina Flores, MD (35:31)
  • Case: A man in his mid-70s with metastatic adenocarcinoma of the lung — PD-L1 1% — Dr Ibrahim (37:42)
• Current Treatment Paradigm for Small Cell Lung Cancer (SCLC)
  • Case: A man in his late 50s with extensive-stage SCLC — Rohit Gosain, MD (47:41)
  • Case: A woman in her mid-60s with limited-stage SCLC — Ranju Gupta, MD (55:33)

CME information and select publications